BEVERLY, Massachusetts—Inogen, Inc., a medical technology company offering respiratory products for use in the homecare setting, announced the appointment of Vafa Jamali as an independent director to the Inogen board of directors, effective on the date of the company’s 2026 annual meeting, or June 15th if earlier.
“Inogen is well positioned to drive meaningful growth, supported by its strong foundation in portable oxygen and an expanded, diversified product portfolio, as health care systems continue to shift care into the home,” said Jamali. “The company’s clear strategic direction and improved financial profile provide a solid foundation for the opportunities ahead, and I look forward to working closely with the board and management to help guide Inogen’s continued progress.”
Prior to ZimVie, most notably, Jamali spent nearly 12 years at Covidien and Medtronic, where he most recently served as senior vice president and president of the respiratory, gastrointestinal and informatics division.
“We are pleased to welcome Vafa to the Board and look forward to benefiting from his unique perspectives,” said Beth Mora, chairperson of the board. “Throughout his many years of leading medical device companies, Vafa has established a track record of driving strategic execution and delivering sustained growth. As we continue advancing our transformation from a single product oxygen company into a diversified respiratory care platform, we believe Vafa’s insight and direction will help guide our management team to execute on its path forward and continue to deliver strong top-line growth and improve profitability.”
In connection with Jamali’s appointment, the company has entered into a cooperation agreement with Kent Lake Partners LP, Kent Lake PR LLC and Benjamin Natter (collectively, “Kent Lake”). The agreement includes customary standstill, voting and other provisions. The agreement will be filed by the company with the U.S. Securities and Exchange Commission as an exhibit to a Current Report on Form 8-K.